Results 231 to 240 of about 64,427 (282)
Some of the next articles are maybe not open access.
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2009
Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents, so-called small molecules. They have a high selectivity against a specific molecular target known to be the cause for the establishment and maintenance of the malignant phenotype ...
C. Waller
semanticscholar +8 more sources
Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents, so-called small molecules. They have a high selectivity against a specific molecular target known to be the cause for the establishment and maintenance of the malignant phenotype ...
C. Waller
semanticscholar +8 more sources
Profiles of Drug Substances, Excipients and Related Methodology, 2014
Imatinib (INN), marketed by Novartis as Gleevec (United States) or Glivec (Europe/Australia/Latin America), received Food & Drug Administration (FDA) approval in May 2001 and is a tyrosine kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.
Ahmed H. Bakheit +2 more
openaire +4 more sources
Imatinib (INN), marketed by Novartis as Gleevec (United States) or Glivec (Europe/Australia/Latin America), received Food & Drug Administration (FDA) approval in May 2001 and is a tyrosine kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.
Ahmed H. Bakheit +2 more
openaire +4 more sources
Drugs, 2003 Imatinib mesylate (imatinib) is an orally administered competitive inhibitor of the tyrosine kinases associated with the KIT protein (stem cell factor receptor), ABL protein and platelet-derived growth factor receptors. The KIT tyrosine kinase is abnormally expressed in gastrointestinal stromal tumour (GIST), a rare neoplasm for which there has been no
Caroline M. Perry, Katherine F Croom
semanticscholar +6 more sources
AAPS PharmSciTech, 2021
Neurodegenerative diseases like Alzheimer’s disease require treatment where it is essential for drug to reach brain. Nose to brain delivery of drugs enables direct transport to brain bypassing blood brain barrier. Imatinib mesylate, an anti-cancer agent,
Raju Saka, Naveen Chella, Wahid Khan
semanticscholar +1 more source
Neurodegenerative diseases like Alzheimer’s disease require treatment where it is essential for drug to reach brain. Nose to brain delivery of drugs enables direct transport to brain bypassing blood brain barrier. Imatinib mesylate, an anti-cancer agent,
Raju Saka, Naveen Chella, Wahid Khan
semanticscholar +1 more source
Journal of Separation Science, 2020
The efficiency of a molecularly imprinted polymer as a selective packing material for solid-phase extraction of imatinib mesylate sorption was investigated.
Atefeh Kazemi +2 more
semanticscholar +1 more source
The efficiency of a molecularly imprinted polymer as a selective packing material for solid-phase extraction of imatinib mesylate sorption was investigated.
Atefeh Kazemi +2 more
semanticscholar +1 more source
Effects of imatinib mesylate in osteoblastogenesis
Experimental Hematology, 2009Imatinib mesylate (IM), a tyrosine kinase inhibitor currently used in chronic myeloid leukemia (CML), may also affect the growth of other cellular systems besides CML cells. Because it has been reported that IM may affect bone tissue remodeling, we evaluated the effects of IM on osteoblastic differentiation of human bone marrow mesenchymal stem cells ...
TIBULLO D +8 more
openaire +4 more sources
Dysregulation of bone remodeling by imatinib mesylate [PDF]
Blood, 2010 AbstractImatinib mesylate is a rationally designed tyrosine kinase inhibitor that has revolutionized the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Although the efficacy and tolerability of imatinib are a vast improvement over conventional chemotherapies, the drug exhibits off-target effects. An unanticipated side effect
Vandyke, K. +4 more
openaire +3 more sources
In Analysis, 2019
Fe3O4 nanoparticles with chitosan grafted onto poly(N-vinylcaprolactam) copolymers are synthesized and showed dual sensitivity to temperature and pH. The nanoparticles were characterized by different techniques and two aspects of their applications were ...
Hamed Sahebi +3 more
semanticscholar +1 more source
Fe3O4 nanoparticles with chitosan grafted onto poly(N-vinylcaprolactam) copolymers are synthesized and showed dual sensitivity to temperature and pH. The nanoparticles were characterized by different techniques and two aspects of their applications were ...
Hamed Sahebi +3 more
semanticscholar +1 more source
An evaluation of the cardiotoxicity of imatinib mesylate
Leukemia Research, 2008We studied 103 consecutive patients with chronic myeloid leukaemia on treatment with imatinib (IM) and 57 patients with chronic myeloproliferative disorders not treated with IM in order to evaluate its cardiotoxicity. There was no statistical difference regarding cardiac symptoms and signs, BNP levels and echocardiographic measurements for IM and ...
Antonio Luiz Pinho Ribeiro +6 more
openaire +3 more sources
Pharmaceutical Nanotechnology, 2019
Imatinib Mesylate loaded Nanospongs (NSPs) were prepared, and evaluated for its pharmacokinetic behaviour in Han Wistor rats. The NSPs were prepared and optimized by 32 full factorial design, β-cyclodextrin (X1) and Diphenyl Carbonate (X2) as independent
M. Kamble +3 more
semanticscholar +1 more source
Imatinib Mesylate loaded Nanospongs (NSPs) were prepared, and evaluated for its pharmacokinetic behaviour in Han Wistor rats. The NSPs were prepared and optimized by 32 full factorial design, β-cyclodextrin (X1) and Diphenyl Carbonate (X2) as independent
M. Kamble +3 more
semanticscholar +1 more source